BioNTech SE - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12 years of age or above, the regulator announced.

Novavax gets FDA nod for updated Covid-19 vaccine for 12 years and above

HQ Team October 4, 2023: The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12.

by HealthQuill
October 4, 2023
0 Comments

German biotechnology company, BioNTech SE announced a $ 90 million program in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for mpox.

Drugs Health Pharma

Germany’s BioNTech, CEPI in $90m pact for mpox vaccine

HQ Team September 18, 2023: German biotechnology company, BioNTech SE announced a $ 90 million program in partnership with the Coalition for Epidemic.